Wisconsin Collaborative for Quality Healthcare

View Our Reports

print this page
Your Search Results: 13 Clinics in the ProHealth Care health system


The results below represent 49,236 men and women who should have had a colorectal cancer screening. Read More About This Measure

Reporting Period:

Sort By Rank | Sort By Name  
Btn Export
ProHealth Medical Group, Inc. (Oconomowoc - Corporate Center Dr.)
N=5329
79.00 %
View Historical Data
ProHealth Medical Group, Inc. Brookfield
N=3608
78.88 %
View Historical Data
ProHealth Medical Group, Inc. Delafield

The number of patients or providers is too small for
purposes of reliably reporting performance
ProHealth Medical Group, Inc. Hartland
N=4862
80.63 %
View Historical Data
ProHealth Medical Group, Inc. Mukwonago
N=7081
79.11 %
View Historical Data
ProHealth Medical Group, Inc. Muskego
N=3667
79.85 %
View Historical Data
ProHealth Medical Group, Inc. New Berlin
N=4430
82.53 %
View Historical Data
ProHealth Medical Group, Inc. Pewaukee
N=6422
80.33 %
View Historical Data
ProHealth Medical Group, Inc. Sussex
N=2123
79.37 %
View Historical Data
ProHealth Medical Group, Inc. Watertown

The number of patients or providers is too small for
purposes of reliably reporting performance
ProHealth Medical Group, Inc. Waukesha Big Bend
N=4975
79.86 %
View Historical Data
ProHealth Medical Group, Inc. Waukesha Moreland
N=6739
83.32 %
View Historical Data
ProHealth Medical Group, Inc.Oconomowoc (OB/Gyn Clinic at Oconomowoc Memorial Hospital)

The number of patients or providers is too small for
purposes of reliably reporting performance

The United States Preventive Services Task Force (USPSTF) strongly recommends that clinicians screen men and women, at age 50 and older for colorectal cancer. The optimal interval for screening depends on the test. Annual fecal occult blood testing (FOBT)/Fecal Immunoassay Test (FIT) offers greater reductions in mortality rates than biennial screening. A 10-year interval has been recommended for colonoscopy, but a 5-year interval is recommended for flexible sigmoidoscopies because of their lower sensitivity. Fecal DNA Screening (Cologuard test) has been added as a new option for screening in 2015 (recommended interval every three years). The USPSTF concluded that the benefits from screening for colorectal cancer substantially outweigh potential harms, and that regardless of screening strategy chosen, it is likely to be cost-effective. In persons identified as being at high-risk by their health care providers, initiating screening at an earlier age is reasonable. It is recommended that all adults speak with their health care providers to determine, on an individual basis, the age at which to begin and end screenings, the best type of screening for individual circumstances, and the frequency of these screenings.


Disclaimer: Measures reported by WCHQ healthcare organizations represent a specific aspect of care in relation to an evidence-based standard, but are not clinical guidelines and do not establish standards of care.